keyword
MENU ▼
Read by QxMD icon Read
search

Biologics uveitis

keyword
https://www.readbyqxmd.com/read/29774506/therapeutic-potential-of-mesenchymal-stem-cell-derived-exosomes-in-the-treatment-of-eye-diseases
#1
C Randall Harrell, Bojana Simovic Markovic, Crissy Fellabaum, Aleksandar Arsenijevic, Valentin Djonov, Nebojsa Arsenijevic, Vladislav Volarevic
Mesenchymal stem cells (MSCs) were, due to their immunomodulatory and pro-angiogenic characteristics, extensively explored as new therapeutic agents in cell-based therapy of uveitis, glaucoma, retinal and ocular surface diseases.Since it was recently revealed that exosomes play an important role in biological functions of MSCs, herewith we summarized current knowledge about the morphology, structure, phenotype and functional characteristics of MSC-derived exosomes emphasizing their therapeutic potential in the treatment of eye diseases...
May 18, 2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29773271/juvenile-idiopathic-arthritis-associated-uveitis
#2
REVIEW
Ethan S Sen, A V Ramanan
Juvenile idiopathic arthritis (JIA) is the commonest rheumatic disease in children and JIA-associated uveitis its most frequent extra-articular manifestation. The uveitis is potentially sight-threatening and thus carries a considerable risk of morbidity with associated reduction in quality of life. The commonest form of uveitis seen in association with JIA is chronic anterior uveitis, which is almost always asymptomatic in the initial stages. Therefore, screening for JIA-associated uveitis in at-risk patients is essential...
August 2017: Best Practice & Research. Clinical Rheumatology
https://www.readbyqxmd.com/read/29729445/emerging-role-of-il-35-in-inflammatory-autoimmune-diseases
#3
REVIEW
Lin-Chong Su, Xiao-Yan Liu, An-Fang Huang, Wang-Dong Xu
Interleukin 35 (IL-35) is the recently identified member of the IL-12 family of cytokines and provides the possibility to be a target for new therapies for autoimmune, inflammatory diseases. It is composed of an α chain (p35) and a β chain (EBI3). IL-35 mediates signaling by binding to its receptors, activates subsequent signaling pathways, and therefore, regulates the differentiation, function of T, B cells, macrophages, dendritic cells. Recent findings have shown abnormal expression of IL-35 in inflammatory autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, psoriasis, multiple sclerosis, autoimmune hepatitis, experimental autoimmune uveitis...
May 3, 2018: Autoimmunity Reviews
https://www.readbyqxmd.com/read/29656829/-uveitis-treated-with-biotherapy-and-or-dmard-analysis-from-the-french-pharmacovigilance-study-base
#4
L Cabane, S Baillif, B Baldin, V Breuil, L Euller-Ziegler, N Tieulié
PURPOSE: To report the characteristics of uveitis cases occurring while on biologic therapy or disease-modifying antirheumatic drugs (DMARDs) reported to the French national pharmacovigilance database. METHODS: All the uveitis cases occurring in patients with chronic rheumatologic diseases, chronic inflammatory intestinal diseases or connective tissue diseases, while treated with DMARDs and/or biologic therapies between 2000 and 2015 and reported to the French National Pharmacovigilance Database were collected...
April 13, 2018: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/29649840/-therapeutic-concepts-for-treatment-of-patients-with-non-infectious-uveitis-biologic-disease-modifying-antirheumatic-drugs
#5
Karoline Walscheid, Uwe Pleyer, Arnd Heiligenhaus
Biologic disease modifying antirheumatic drugs (bDMARDs) can be highly efficient in the treatment of various non-infectious uveitis entities. Currently, the TNF-α-inhibitor Adalimumab is the only in-label therapeutic option, whereas, all other bDMARDs need to be given as an off-label therapy. bDMARDs are indicated in diseases refractory to conventional synthetic DMARD therapy and/or systemic steroids, or in patients in whom treatment with those is not possible due to side effects. Therapeutic mechanisms currently employed are cytokine-specific (interferons, inhibition of TNF-α or of interleukin [IL]-1-, IL-6- or IL-17-signalling), inhibit T cell costimulation (CTLA-4 fusion protein), or act via depletion of B cells (anti-CD20)...
April 12, 2018: Klinische Monatsblätter Für Augenheilkunde
https://www.readbyqxmd.com/read/29611087/long-term-retention-rates-of-adalimumab-and-infliximab-in-non-infectious-intermediate-posterior-and-panuveitis
#6
Claudia Fabiani, Antonio Vitale, Giacomo Emmi, Alice Bitossi, Giuseppe Lopalco, Jurgen Sota, Silvana Guerriero, Ida Orlando, Marco Capozzoli, Fiorella Fusco, Francesco Rana, Florenzo Iannone, Bruno Frediani, Mauro Galeazzi, Lorenzo Vannozzi, Gian Marco Tosi, Luca Cantarini
The aim of the present study was to compare long-term adalimumab (ADA) and infliximab (IFX) retention rates in patients with intermediate, posterior, or panuveitis. Additional aims are as follows: (i) to identify any difference in the causes of treatment discontinuation between patients treated with ADA and IFX; (ii) to assess any impact of demographic features, concomitant treatments, and different lines of biologic therapy on ADA and IFX retention rates; and (iii) to identify any correlation between ADA and IFX treatment duration and the age at uveitis onset, the age at onset of the associated systemic diseases, and the age at the start of treatment...
April 3, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29610003/-therapeutic-strategy-for-the-treatment-of-non-infectious-uveitis-proposed-by-an-expert-panel
#7
E Diwo, P Sève, S Trad, P Bielefeld, D Sène, S Abad, A Brézin, P Quartier, I Koné Paut, M Weber, C Chiquet, M H Errera, J Sellam, P Cacoub, G Kaplanski, L Kodjikian, B Bodaghi, D Saadoun
Conventional immunosuppressive drugs, anti-TNF alpha and other biotherapies used in clinical practice are capable of controlling non-infectious anterior uveitis, posterior uveitis and panuveitis. The present work has been led by a multidisciplinary panel of experts, internists, rheumatologists and ophthalmologists and is based on a review of the literature. In case of corticodependency or sight-threatening disease, conventional immunosuppressive drugs (methotrexate, azathioprine and mycophenolate mofetil) and/or anti-TNF alpha (adalimumab, infliximab) are used to achieve and maintain remission...
March 30, 2018: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/29602570/successful-optimization-of-adalimumab-therapy-in-refractory-uveitis-due-to-beh%C3%A3-et-s-disease
#8
José Luis Martín-Varillas, Vanesa Calvo-Río, Emma Beltrán, Juan Sánchez-Bursón, Marina Mesquida, Alfredo Adán, María Victoria Hernandez, Marisa Hernández Garfella, Elia Valls Pascual, Lucía Martínez-Costa, Agustí Sellas-Fernández, Miguel Cordero-Coma, Manuel Díaz-Llopis, Roberto Gallego, David Salom, Norberto Ortego, José L García-Serrano, José-Luis Callejas-Rubio, José M Herreras, Ángel García-Aparicio, Olga Maíz, Ana Blanco, Ignacio Torre, David Díaz-Valle, Esperanza Pato, Elena Aurrecoechea, Miguel A Caracuel, Fernando Gamero, Enrique Minguez, Carmen Carrasco-Cubero, Alejandro Olive, Julio Vázquez, Oscar Ruiz-Moreno, Javier Manero, Santiago Muñoz-Fernández, Myriam Gandía Martinez, Esteban Rubio-Romero, F Javier Toyos-Sáenz de Miera, Francisco Javier López Longo, Joan M Nolla, Marcelino Revenga, Carmen González-Vela, Javier Loricera, Belén Atienza-Mateo, Rosalía Demetrio-Pablo, José Luis Hernández, Miguel A González-Gay, Ricardo Blanco
PURPOSE: To assess efficacy, safety, and cost-effectiveness of adalimumab (ADA) therapy optimization in a large series of patients with uveitis due to Behçet disease (BD) who achieved remission after the use of this biologic agent. DESIGN: Open-label multicenter study of ADA-treated patients with BD uveitis refractory to conventional immunosuppressants. SUBJECTS: Sixty-five of 74 patients with uveitis due to BD, who achieved remission after a median ADA duration of 6 (range, 3-12) months...
March 27, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29595276/-axial-spondyloarthritis
#9
Leona Procházková, Vladimír Červeňák, Miroslav Souček
Axial spondyloarthritis (axSpA) is a common name for the non-radiographic form of the disease and radiographic axial spondyloarthritis, known as ankylosing spondylitis (AS). The disease is typically manifested at a young age, characterized by affection of axial skeleton, and in the most severe form can lead to complete ankylosis of the spine. Etiology of diseases have not yet been clarified, however, the genetic background, especially the binding to HLA-B27 antigen, is obvious. Clinical manifestations are dominated by chronic pain in the lower pain or buttocks that occurred in young age, in a large proportion of patients having the character of so-called inflammatory pain...
2018: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29577629/efficacy-and-safety-of-intravitreal-anti-tumour-necrosis-factor-drugs-in-adults-with-non-infectious-uveitis-a-systematic-review
#10
REVIEW
Inês Leal, Filipe B Rodrigues, David Cordeiro Sousa, Vasco C Romão, Gonçalo S Duarte, Ester Carreño, Andrew D Dick, Carlos Marques-Neves, João Costa, João Eurico Fonseca
Anti-tumour necrosis factor (TNF) drugs have been extensively used in non-infectious uveitis (NIU), when corticosteroids or conventional immunosuppressive drugs cannot adequately control inflammation or intolerable side-effects occur. However, systemic anti-TNF therapies are also associated with a myriad of side-effects. Therefore, intravitreal administration of anti-TNF biologics has been employed to minimize patient morbidity and systemic adverse effects, while maintaining therapeutic effectivity. We undertook a systematic review to determine evidence of efficacy and safety of intravitreal administration of anti-TNF drugs in adults with NIU...
March 25, 2018: Acta Ophthalmologica
https://www.readbyqxmd.com/read/29559410/angiogenic-and-immunologic-proteins-identified-by-deep-proteomic-profiling-of-human-retinal-and-choroidal-vascular-endothelial-cells-potential-targets-for-new-biologic-drugs
#11
Justine R Smith, Larry L David, Binoy Appukuttan, Phillip A Wilmarth
Diseases that involve retinal or choroidal vascular endothelial cells are leading causes of vision loss: age-related macular degeneration, retinal ischemic vasculopathies and non-infectious posterior uveitis. Proteins differentially expressed by these endothelial cell populations are potential drug targets. We used deep proteomic profiling to define the molecular phenotype of human retinal and choroidal endothelial cells at the protein level. MethodsRetinal and choroidal vascular endothelial cells were separately isolated from five human eye pairs by selection on CD31...
March 17, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29490353/association-of-long-noncoding-rnas-polymorphisms-with-ankylosing-spondylitis-vogt-koyanagi-harada-disease-and-behcet-s-disease
#12
Yingying Yue, Jun Zhang, Lu Yang, Shengyun Liu, Jian Qi, Qingfeng Cao, Chunjiang Zhou, Yao Wang, Aize Kijlstra, Peizeng Yang, Shengping Hou
Purpose: Long noncoding RNAs (lncRNAs) are emerging as important regulators of inflammatory immune responses, whereby genetic variants may affect this biologic function. This study aimed to investigate the association of 110 single nucleotide polymorphisms (SNPs) of lncRNAs, known to be associated with autoimmune disease, in patients with ocular Vogt-Koyanagi-Harada (VKH) disease, Behcet's disease (BD), and acute anterior uveitis (AAU) with or without ankylosing spondylitis (AS). Methods: A two-stage case-control study was performed on 1626 VKH patients, 384 BD patients, 624 AAU with AS, 751 AAU without AS, 720 AS without AAU, and 3305 healthy subjects...
February 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29488243/hla-drb1-04-05-in-two-cases-of-vogt-koyanagi-harada-disease-like-uveitis-developing-from-an-advanced-melanoma-patient-treated-by-sequential-administration-of-nivolumab-and-dabrafenib-trametinib-therapy
#13
Taku Fujimura, Yumi Kambayashi, Kayo Tanita, Yota Sato, Takanori Hidaka, Astushi Otsuka, Hidenori Tanaka, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba
Although uveitis is reported as a rare adverse event (AE) associated with dabrafenib/trametinib therapy or nivolumab, the occurrence of severe uveitis is extremely rare. We describe two cases of Vogt-Koyanagi-Harada (VKH)-like uveitis developing after the sequential administration of nivolumab and dabrafenib/trametinib therapy. Interestingly, both cases had HLA-DRB1*04:05, which is strongly associated with VKH disease, and achieved biologically complete remission after the treatment for uveitis. Our cases suggest a possible correlation between VKH-like uveitis as an AE and the clinical outcomes of sequential administration of nivolumab and dabrafenib/trametinib therapy for the treatment of advanced melanoma...
February 27, 2018: Journal of Dermatology
https://www.readbyqxmd.com/read/29471416/anti-interleukin-6-receptor-tocilizumab-in-refractory-uveitis-associated-with-beh%C3%A3-et-s-disease-multicentre-retrospective-study
#14
Belén Atienza-Mateo, Vanesa Calvo-Río, Emma Beltrán, Lucía Martínez-Costa, Elia Valls-Pascual, Marisa Hernández-Garfella, Antonio Atanes, Miguel Cordero-Coma, Joan Miquel Nolla, Carmen Carrasco-Cubero, Javier Loricera, María C González-Vela, Nuria Vegas-Revenga, Carlos Fernández-Díaz, Rosalía Demetrio-Pablo, Lucía C Domínguez-Casas, José Luis Martín-Varillas, Natalia Palmou-Fontana, José L Hernández, Miguel Á González-Gay, Ricardo Blanco
Objective: To assess the efficacy of tocilizumab (TCZ) in refractory uveitis of Behçet's disease (BD). Methods: Multicentre study of patients with BD-associated uveitis. Patients were refractory to conventional and biologic immunosuppressive drugs. The main outcome measures were intraocular inflammation, macular thickness, visual acuity and corticosteroid-sparing effects. Results: We studied 11 patients (7 men) (20 affected eyes); median age 35 years...
May 1, 2018: Rheumatology
https://www.readbyqxmd.com/read/29455252/the-effect-of-anti-tumor-necrosis-factor-alpha-agents-on-the-outcome-in-pediatric-uveitis-of-diverse-etiologies
#15
Iris Deitch, Radgonde Amer, Oren Tomkins-Netzer, Zohar Habot-Wilner, Ronit Friling, Ron Neumann, Michal Kramer
PURPOSE: This study aimed to report the clinical outcome of children with uveitis treated with anti-tumor necrosis factor alpha (TNF-α) agents. METHODS: This included a retrospective cohort study. Children with uveitis treated with infliximab or adalimumab in 2008-2014 at five dedicated uveitis clinics were identified by database search. Their medical records were reviewed for demographic data, clinical presentation, ocular complications, and visual outcome. Systemic side effects and the steroid-sparing effect of treatment were documented...
April 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29449499/clinical-correlates-outcomes-and-predictors-of-inflammatory-ocular-disease-associated-with-rheumatoid-arthritis-in-the-biologic-era
#16
Cristian Caimmi, Cynthia S Crowson, Wendy M Smith, Eric L Matteson, Ashima Makol
OBJECTIVE: Inflammatory ocular disease (IOD) is a rare but severe extraarticular manifestation of rheumatoid arthritis (ExRA) with high mortality. The aim of our study was to examine clinical characteristics of IOD in rheumatoid arthritis (RA) and their effect on disease severity and outcomes in recent years. METHODS: A retrospective cohort of RA patients with IOD evaluated between 1996 and 2013 was assembled and compared to RA comparators without IOD and matched for age, sex, and disease duration...
May 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29439003/impact-of-red-and-processed-meat-and-fibre-intake-on-treatment-outcomes-among-patients-with-chronic-inflammatory-diseases-protocol-for-a-prospective-cohort-study-of-prognostic-factors-and-personalised-medicine
#17
Robin Christensen, Berit L Heitmann, Karina Winther Andersen, Ole Haagen Nielsen, Signe Bek Sørensen, Mohamad Jawhara, Anette Bygum, Lone Hvid, Jakob Grauslund, Jimmi Wied, Henning Glerup, Ulrich Fredberg, Jan Alexander Villadsen, Søren Geill Kjær, Jan Fallingborg, Seyed A G R Moghadd, Torben Knudsen, Jacob Brodersen, Jesper Frøjk, Jens Frederik Dahlerup, Anders Bo Bojesen, Grith Lykke Sorensen, Steffen Thiel, Nils J Færgeman, Ivan Brandslund, Tue Bjerg Bennike, Allan Stensballe, Erik Berg Schmidt, Andre Franke, David Ellinghaus, Philip Rosenstiel, Jeroen Raes, Mette Boye, Lars Werner, Charlotte Lindgaard Nielsen, Heidi Lausten Munk, Anders Bathum Nexøe, Torkell Ellingsen, Uffe Holmskov, Jens Kjeldsen, Vibeke Andersen
INTRODUCTION: Chronic inflammatory diseases (CIDs) are frequently treated with biological medications, specifically tumour necrosis factor inhibitors (TNFi)). These medications inhibit the pro-inflammatory molecule TNF alpha, which has been strongly implicated in the aetiology of these diseases. Up to one-third of patients do not, however, respond to biologics, and lifestyle factors are assumed to affect treatment outcomes. Little is known about the effects of dietary lifestyle as a prognostic factor that may enable personalised medicine...
February 8, 2018: BMJ Open
https://www.readbyqxmd.com/read/29395599/-anterior-uveitis
#18
REVIEW
J Gueudry, M Muraine
Anterior uveitis is the most common form of uveitis. There are several known and many possible etiologies for anterior uveitis. After examining the posterior segment and ruling out masquerade syndromes, the main step of etiologic diagnosis is clinical characterization. It is essential to establish unilateral versus bilateral involvement and presence or absence of granulomatous features. Subsequently, a work-up may be obtained which then helps to confirm diagnostic hypotheses based on the detailed history and clinical examination...
February 2018: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/29338721/infectious-keratoconjunctivitis-in-semi-domesticated-eurasian-tundra-reindeer-rangifer-tarandus-tarandus-microbiological-study-of-clinically-affected-and-unaffected-animals-with-special-reference-to-cervid-herpesvirus-2
#19
Javier Sánchez Romano, Torill Mørk, Sauli Laaksonen, Erik Ågren, Ingebjørg H Nymo, Marianne Sunde, Morten Tryland
BACKGROUND: Infectious keratoconjunctivitis (IKC) is one of the most common ocular diseases in ruminants worldwide. In addition to keratitis and conjunctivitis, animals with IKC can develop uveitis, corneal ulcer, and in severe cases, blindness. The bacteria Moraxella spp. has been described as the primary causative agent of infectious bovine keratoconjunctivitis (IBK) in cattle (Bos taurus), while Chlamydia spp. and Mycoplasma conjunctivae are considered the main causative agents of IKC in sheep (Ovis aries)...
January 16, 2018: BMC Veterinary Research
https://www.readbyqxmd.com/read/29310963/guidance-on-noncorticosteroid-systemic-immunomodulatory-therapy-in-noninfectious-uveitis-fundamentals-of-care-for-uveitis-focus-initiative
#20
REVIEW
Andrew D Dick, James T Rosenbaum, Hassan A Al-Dhibi, Rubens Belfort, Antoine P Brézin, Soon Phaik Chee, Janet L Davis, Athimalaipet V Ramanan, Koh-Hei Sonoda, Ester Carreño, Heloisa Nascimento, Sawsen Salah, Sherveen Salek, Jay Siak, Laura Steeples
TOPIC: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. CLINICAL RELEVANCE: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. METHODS: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science)...
January 6, 2018: Ophthalmology
keyword
keyword
53757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"